Skip to content
    MD
    Earnings call· Jun 2026(Q2 FY26)

    Pediatrix Medical Group Q2 FY26 earnings call MD

    Aug 4, 2026 Source

    Executive summary

    Pediatrix Medical Group Q2 FY26 — Solid Adjusted EBITDA and Share Buybacks

    Pediatrix Medical Group delivered a solid second quarter, meeting expectations with strong adjusted EBITDA and reaffirming its full-year outlook. The company continues to leverage its financial strength for share repurchases and strategic growth opportunities in women's and children's medicine, including telehybrid services. While facing slight volume declines, favorable pricing dynamics from RCM collections, payer mix, and acuity offset these pressures.

    Highlights

    5

    • Adjusted EBITDA reached $76 million, aligning with expectations for the quarter.

    • The company reaffirmed its full-year 2026 adjusted EBITDA outlook of $280 million to $300 million.

    • Just under 2 million shares were repurchased in the quarter, contributing to a total of 7 million shares bought back since August 2025.

    • Same unit pricing increased by 4%, driven by strong RCM collections, favorable payer mix, and increased patient acuity.

    • Payer mix improved by 135 basis points year-over-year and 120 basis points quarter-over-quarter.

    Concerns

    4

    • Modestly lower volumes were observed, primarily in neonatology, with NICU days down 3%.

    • Same unit patient service volumes decreased by 2% year-over-year.

    • Practice-level FW&B expenses rose due to increases in salary and malpractice expenses.

    • G&A expense increased year-over-year, primarily related to executive transition costs.

    Guidance & targets

    2
    CategoryTargetConfidence
    Adjusted EBITDA
    $280 million to $300 million
    high materiality
    High
    Adjusted EBITDA
    fairly ratable
    medium materiality
    Medium

    Operational metrics

    13
    Shares repurchased
    just under 2 million
    Q2 FY26

    Total buybacks since August 2025 are 7 million shares.

    Shares outstanding
    81 milliondown from 87 million at end of Q2 FY25
    Q2 FY26

    Reflects impact of share repurchases.

    Cash balance
    $285 million
    Q2 FY26

    Strong balance sheet enables support for practices and growth.

    Total debt
    $584 million
    Q2 FY26

    Part of the company's financial strength.

    Net debt
    just over $295 million
    Q2 FY26

    Calculated with cash of $289 million and total debt of $584 million.

    Accounts receivable DSO
    42.5 daysdown just under four days year over year
    June 30th

    Fairly unchanged from March 31st and December 31st, primarily related to improved cash collections at existing units.

    Same unit pricing growth
    4%
    Q2 FY26

    A key driver of consolidated revenue increase.

    Salary expense growth
    3% to 3.5%
    past several quarters

    Kept in a tight band, consistent with ranges seen for the last 18 months, down from mid-single digits historically.

    G&A expense
    $5.8 millioncompared to $5.3 million in the prior year
    Q2 FY26

    Most of the growth was related to one-time-ish executive transition costs.

    Other non-operating expense
    $2.9 millioncompared to $4.9 million for the prior year period
    Q2 FY26

    Reflects changes in interest rates and cash balances.

    Number of MFMs
    over 170
    current

    Represents the largest multi-state footprint in the nation for Maternal Fetal Medicine.

    Number of NICUs
    over 360
    current

    The largest in the country, handling more high-acuity patients than anyone else.

    Number of hospitals with OBH relationships
    over 400
    current

    Leveraged for expanding the OBH footprint.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendsdown 3%%
    Same facility volumesdown 2%%
    Payer mix supplemental paymentsimproved by 135 basis pointsbps
    Adjusted EPS EBITDA leverage guidance$76 millionUSD

    Deals & partnerships

    2
    VariousRecent acquisitions contributing to non-Same Unit activity

    Consolidated revenue increased by 4%, driven by non-Same Unit activity, primarily recent acquisitions.

    Outside JV and capital investorsExploring potential opportunities to augment strengths in women's and children's medicine

    Actively looking at possible growth avenues within women's and children's medicine, including potential opportunities to augment our strengths by working with outside JV and capital investors.

    Risks & headwinds

    4
    Modestly lower volumesQ2 FY26

    NICU days down 3%; Same unit patient service volumes down 2%

    Mitigation: Offset by strong RCM collections, favorable payer mix, and increased patient acuity; company expects full year volumes to be flat to slightly down and does not see it as an ongoing trend.

    Increased practice-level expensesQ2 FY26

    FW&B expenses increased year over year

    Mitigation: Salary growth remained in a tight band (3% to 3.5%); tight controls in place.

    Dissipation of RCM collections tailwindsecond half of 2026

    RCM collections tailwind will begin to dissipate

    Mitigation: Anticipate acuity will continue to be a positive factor for pricing.

    Increased G&A expenseQ2 FY26

    G&A expense increased to $5.8 million compared to $5.3 million in prior year

    Mitigation: Primarily related to one-time-ish executive transition costs; expected to step down in H2.

    What to watch in Q3 FY26

    4

    RCM collections tailwind

    Second half of 2026
    CurrentBiggest contributor to 4% same unit pricing growth
    TargetDissipation of tailwind

    Why it matters

    RCM collections have been a primary driver of pricing growth; its dissipation could impact future revenue growth.

    The biggest contributor is the RCM collections... we do anticipate that the RCM collections piece that we've been seeing that tailwind will begin to dissipate in the last in the second half of 2026.

    Q&A highlights

    6

    Why is Pediatrix's payer mix stable compared to peers, what consumer trends drive it, and what are the expectations for H2?

    Management attributes payer mix stability to the high value of health insurance for pregnant individuals. They have not observed the negative effects seen by other healthcare companies and see no signs of change to date, despite broader concerns about subsidy lapses.

    “We have not seen the same effect that others have experienced. You know, we can guess that it has something to do with the fact that if you're pregnant, then the relative value of the pregnancy is going to be higher. of insurance is a lot greater for you than it might be for somebody else.”

    asked by Matthew Mardula · answered by Mark Ordan

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Focus on Telehybrid Medicine

    Pediatrix is actively developing a significant telehybrid medicine function to complement its physical services nationwide. This initiative leverages the company's extensive footprint, including over 170 Maternal Fetal Medicine (MFM) specialists and more than 360 Neonatal Intensive Care Units (NICUs) across 32 states. Management believes that combining telemedicine with physical patient visits offers a superior model, enhancing access to care while ensuring hands-on intervention when necessary, particularly for high-acuity patients.

    02

    OBH Footprint Expansion and Growth Avenues

    The company is expanding its Obstetric Hospitalist (OBH) footprint, capitalizing on its established relationships with over 400 hospitals. Pediatrix has recruited specialized leaders to drive growth in both telehybrid medicine and OBH services. Beyond organic growth, the company is actively exploring external growth avenues within women's and children's medicine, including potential acquisitions and collaborations with joint venture and capital investors, seeking opportunities that offer clear operating and financial benefits.

    03

    Capital Allocation and Financial Strength

    Pediatrix maintains a strong balance sheet, reporting a cash balance of $285 million and total debt of $584 million, resulting in net debt of just over $295 million. This financial strength supports consistent investment in practices, quality programs, research, and growth initiatives. The company continues its share repurchase program, having bought back just under 2 million shares in the quarter and 7 million shares since August 2025, reducing shares outstanding to 81 million.

    04

    Pricing Dynamics and Key Drivers

    Same unit pricing increased by 4% in the second quarter, primarily attributed to strong revenue cycle management (RCM) cash collections, a favorable payer mix, and an ongoing rise in patient acuity, particularly within neonatology. Payer mix showed significant improvement, up 135 basis points year-over-year and 120 basis points quarter-over-quarter. While the tailwind from RCM collections is expected to dissipate📎 in the second half of 2026, management anticipates acuity will remain a positive pricing factor.

    05

    Volume Trends and Outlook

    The company experienced modestly lower volumes, with NICU days down 3% and same unit patient service volumes down 2%. These declines were attributed to a tough prior-year comparison and typical seasonal patterns. Despite the current decrease, management does not view this as a long-term trend, expecting overall volumes for the full year to be flat to slightly down. The high-acuity nature of their neonatology services and the potential for telehybrid medicine to reach underserved areas are seen as mitigating factors.

    AI-generated summary of the company’s earnings call. Not investment advice.